These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32503882)

  • 41. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
    Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
    J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Use of HμREL Human Coculture System for Prediction of Intrinsic Clearance and Metabolite Formation for Slowly Metabolized Compounds.
    Hultman Ia; Vedin C; Abrahamsson A; Winiwarter S; Darnell M
    Mol Pharm; 2016 Aug; 13(8):2796-807. PubMed ID: 27377099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selective Suppression of CYP3A4 mRNA and Enzyme Activity by Epidermal Growth Factor in Plated Human Hepatocytes.
    Zhang JG; Wang D; Ho T; Clark RJ; Stresser DM
    Drug Metab Lett; 2017; 11(2):119-127. PubMed ID: 29189189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism.
    Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
    Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):751-767. PubMed ID: 29876844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
    Beumer JH; Pillai VC; Parise RA; Christner SM; Kiesel BF; Rudek MA; Venkataramanan R
    Br J Clin Pharmacol; 2015 Nov; 80(5):1097-108. PubMed ID: 26178713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
    Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of Micropatterned Cocultured Hepatocytes to Evaluate the Inductive Potential and Degradation Rate of Major Xenobiotic Metabolizing Enzymes.
    Dixit V; Moore A; Tsao H; Hariparsad N
    Drug Metab Dispos; 2016 Feb; 44(2):250-61. PubMed ID: 26658225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay.
    Lam JL; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Aug; 34(8):1336-44. PubMed ID: 16698890
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: influence of time between substrate and inducer administration.
    Baneyx G; Parrott N; Meille C; Iliadis A; Lavé T
    Eur J Pharm Sci; 2014 Jun; 56():1-15. PubMed ID: 24530864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of Action of Panaxytriol on Midazolam 1'-Hydroxylation and 4-Hydroxylation Mediated by CYP3A in Liver Microsomes and Rat Primary Hepatocytes.
    He F; Zhang W; Zeng C; Xia C; Xiong Y; Zhang H; Huang S; Liu M
    Biol Pharm Bull; 2015; 38(10):1470-7. PubMed ID: 26424012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of hepatic cytochrome P450s and UDP-glucuronosyltransferases in PXR and CAR double humanized mice treated with rifampicin.
    Lee SY; Lee JY; Kim YM; Kim SK; Oh SJ
    Toxicol Lett; 2015 Jun; 235(2):107-15. PubMed ID: 25835148
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug-Drug Interaction Risk Assessment of Esaxerenone as a Perpetrator by In Vitro Studies and Static and Physiologically Based Pharmacokinetic Models.
    Yamada M; Ishizuka T; Inoue SI; Rozehnal V; Fischer T; Sugiyama D
    Drug Metab Dispos; 2020 Sep; 48(9):769-777. PubMed ID: 32616542
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
    Laille E; Patel M; Jones SF; Burris HA; Infante J; Lemech C; Liu L; Arkenau HT
    J Clin Pharmacol; 2015 Dec; 55(12):1378-85. PubMed ID: 26053962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction.
    Kim S; Dinchuk JE; Anthony MN; Orcutt T; Zoeckler ME; Sauer MB; Mosure KW; Vuppugalla R; Grace JE; Simmermacher J; Dulac HA; Pizzano J; Sinz M
    Drug Metab Dispos; 2010 Jan; 38(1):16-24. PubMed ID: 19833845
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acetaminophen analog N-acetyl-m-aminophenol, but not its reactive metabolite, N-acetyl-p-benzoquinone imine induces CYP3A activity via inhibition of protein degradation.
    Santoh M; Sanoh S; Ohtsuki Y; Ejiri Y; Kotake Y; Ohta S
    Biochem Biophys Res Commun; 2017 May; 486(3):639-644. PubMed ID: 28341123
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.
    Zuo R; Li F; Parikh S; Cao L; Cooper KL; Hong Y; Liu J; Faris RA; Li D; Wang H
    Drug Metab Dispos; 2017 Feb; 45(2):198-207. PubMed ID: 28062541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac.
    Chan TS; Yu H; Moore A; Khetani SR; Tweedie D
    Drug Metab Dispos; 2019 Jan; 47(1):58-66. PubMed ID: 30552098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac.
    Ramsden D; Tweedie DJ; Chan TS; Taub ME; Li Y
    Drug Metab Dispos; 2014 Mar; 42(3):394-406. PubMed ID: 24366904
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
    Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
    Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.